The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Cannabidiol is a negative allosteric modulator of the cannabinoid CB 1 receptor
Open accessAbstract
Background and Purpose: Cannabidiol has been reported to act as an antagonist at cannabinoid CB 1 receptors. We hypothesized that cannabidiol would inhibit cannabinoid agonist activity through negative allosteric modulation of CB 1 receptors. Experimental Approach: Internalization of CB 1 receptors, arrestin2 recruitment, and PLCβ3 and ERK1/2 phosphorylation, were quantified in HEK 293A cells heterologously expressing CB 1 receptors and in the ST Hdh Q7/Q7 cell model of striatal neurons endogenously expressing CB 1 receptors. Cells were treated with 2‐arachidonylglycerol or Δ 9 ‐tetrahydrocannabinol alone and in combination with different concentrations of cannabidiol. Key Results: Cannabidiol reduced the efficacy and potency of 2‐arachidonylglycerol and Δ 9 ‐tetrahydrocannabinol on PLCβ3‐ and ERK1/2‐dependent signalling in cells heterologously (HEK 293A) or endogenously (ST Hdh Q7/Q7 ) expressing CB 1 receptors. By reducing arrestin2 recruitment to CB 1 receptors, cannabidiol treatment prevented internalization of these receptors. The allosteric activity of cannabidiol depended upon polar residues being present at positions 98 and 107 in the extracellular amino terminus of the CB 1 receptor. Conclusions and Implications: Cannabidiol behaved as a non‐competitive negative allosteric modulator of CB 1 receptors. Allosteric modulation, in conjunction with effects not mediated by CB 1 receptors, may explain the in vivo effects of cannabidiol. Allosteric modulators of CB 1 receptors have the potential to treat CNS and peripheral disorders while avoiding the adverse effects associated with orthosteric agonism or antagonism of these receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Cannabidiol (CBD; Epidolex®) acts as a negative allosteric modulator at CB1 receptors [7] and also acts at several other receptors, such as CB2 receptors, serotonin 1A receptors, opioid receptors and several ligand-gated ion channels [8]”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [7]
In the citing paper
“CBD has been termed a negative allosteric modulator at CB1R (Laprairie et al., 2015)”
From The endocannabinoid system as a target for novel anxiolytic drugs (2017) · cites this paper as Laprairie et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The orphan receptor GPR55 is a novel cannabinoid receptor
Ryberg, E., Larsson, N., Sjögren, S., Hjorth, S., Hermansson, N., Leonova, J., Elebring, T., Nilsson, K., Drmota, T., & Greasley, P. J. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707460 · Cited by 1,568
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315
G Protein-Coupled Receptor Allosterism and Complexing
Christopoulos, A., & Kenakin, T. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.323 · Cited by 934
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6978-1 · Cited by 878
Pawson, A. J., Sharman, J. L., Benson, H. E., Faccenda, E., Alexander, S. P. H., Buneman, O. P., Davenport, A. P., McGrath, J. C., Peters, J. A., Southan, C., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt1143 · Cited by 845
Thomas, A., Baillie, G. L., Phillips, A. M., Razdan, R. K., Ross, R. A., & Pertwee, R. G. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707133 · Cited by 763
Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells
Trettel, F. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.19.2799 · Cited by 614
The Concise Guide to PHARMACOLOGY 2013/14: G Protein‐Coupled Receptors
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12445 · Cited by 561
McPartland, J. M., Duncan, M., Marzo, V. D., & Pertwee, R. G. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12944 · Cited by 552
Mechoulam, R., Peters, M., Murillo‐Rodriguez, E., & Hanuš, L. O. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790147 · Cited by 515
Cited by
Sorted by citations
Zou, S., & Kumar, U. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030833 · Cited by 1,448
Phytocannabinoids: a unified critical inventory
Hanuš, L. O., Meyer, S. M., Muñoz, E., Taglialatela-Scafati, O., & Appendino, G. (2016) · Natural Product Reports · doi:10.1039/c6np00074f · Cited by 844
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019) · Antioxidants · doi:10.3390/antiox9010021 · Cited by 889
The pharmacokinetics and the pharmacodynamics of cannabinoids
Lucas, C. J., Galettis, P., & Schneider, J. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13710 · Cited by 724
Practical considerations in medical cannabis administration and dosing
MacCallum, C. A., & Russo, E. B. (2018) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2018.01.004 · Cited by 663
Metadata
- Authors
- Laprairie, R. B., Bagher, A. M., Kelly, M. E. M., & Denovan‐Wright, E. M.
- Affiliations
- Dalhousie University (CA)
- Corresponding author
- Denovan‐Wright, E M
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2015-10
- Volume
- 172
- Issue
- 20
- Pages
- 4790-4805
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- PMC
- PMC4621983
- OpenAlex
- W1945751328
- Cited by
- 1,039
- References
- 47
- Citations by year
- 2026: 92 · 2025: 107 · 2024: 107 · 2023: 107 · 2022: 133 · 2021: 150 · 2020: 125 · 2019: 89 · 2018: 54 · 2017: 49 · 2016: 19 · 2015: 6
- FWCI
- 30.74
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- British Journal of Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (ROP-97185, MOP-97768)
- Killam Trusts
- Nova Scotia Health Research Foundation
- King Abdulaziz University of Saudi Arabia
- Huntington Society of Canada
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- cannabidiol, CB1 receptor, negative allosteric modulation, receptor internalization, ERK1/2 phosphorylation, 2-arachidonoylglycerol, delta-9-tetrahydrocannabinol, allosteric modulators, non-competitive antagonism
- MeSH terms
- Animals, Cannabidiol, Cell Line, Humans, Arrestins, MAP Kinase Signaling System, Receptor, Cannabinoid, CB1, Mice, Phospholipase C beta, HEK293 Cells, Cannabinoid Receptor Modulators
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
